Quick Answer
Metagenomi Therapeutics, Inc. reported Shares Outstanding of 37.62 million shares for fiscal year 2025.
Metagenomi Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 37.62M | +0.5% |
| 2024 | 37.42M | +999.1% |
| 2023 | 3.40M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 37.55M | +0.3% | +0.0% |
| June 30, 2025 | 37.53M | +0.2% | +0.4% |
| March 31, 2025 | 37.38M | -0.2% | -0.1% |
| December 31, 2024 | 37.42M | +999.1% | -0.0% |
| September 30, 2024 | 37.43M | — | -0.1% |
| June 30, 2024 | 37.46M | — | -0.0% |
| March 31, 2024 | 37.47M | — | +1000.5% |
| December 31, 2023 | 3.40M | — | — |
- Metagenomi Therapeutics, Inc. showed an increase of +0.5% in Shares Outstanding compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s shares outstanding has grown by 1005.0% (from 3.40 million shares to 37.62 million shares).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: